



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**2 March 2021**

---

## **Completion of Placement**

Bionomics Limited (ASX:BNO) (**Bionomics**) announces that the placement announced on 9 February 2021 has been completed today with the issue of 110,287,131 fully paid ordinary shares at an issue price of \$0.145 per share, to raise a total of \$15,991,634. The underwriting obligations of Apeiron Investment Group Ltd (**Apeiron**) under the Subscription Agreement (approved by Bionomics' shareholders on 26 August 2020) have now been satisfied, entitling Apeiron to be issued warrants to acquire a further 150,000,000 Bionomics shares at \$0.06 per share.

As foreshadowed in the announcement of 9 February 2021, Bionomics intends to proceed with a pro rata Entitlement Offer to enable all shareholders to acquire shares at \$0.145 per share, being the same price as under the placement. As at the date of this announcement, the offer size, ratio and timetable of the Entitlement Offer have not been determined and will be the subject of a further announcement in due course.

This announcement has been approved by Dr Errol De Souza, Executive Chairman, on behalf of the Board of Directors of Bionomics.

### **FOR FURTHER INFORMATION PLEASE CONTACT:**

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
Bionomics Limited  
31 Dalgleish St,  
Thebarton, South Australia  
+61 8 8354 6100

### **About Bionomics Limited**

Bionomics (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.

[www.bionomics.com.au](http://www.bionomics.com.au)

### **Factors Affecting Future Performance**

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug

candidates (including BNC210), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.